TrialAmerican journal of clinical dermatology2022

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.

Jonathan I Silverberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.